Education
About Us
Working with TipRanks
Follow Us
Theriva Biologics (TOVX)
XASE:TOVX
Total Valuation
Theriva Biologics has a market cap or net worth of $8.04M. The enterprise value is -$4.17M.
Market Cap$8.04M
Enterprise Value-$4.17M
Share Statistics
Theriva Biologics has 45,892,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,892,670
Owned by Insiders0.73%
Owned by Institutions0.26%
Financial Efficiency
Theriva Biologics’s return on equity (ROE) is -1.64 and return on invested capital (ROIC) is -52.10%.
Return on Equity (ROE)-1.64
Return on Assets (ROA)-0.66
Return on Invested Capital (ROIC)-52.10%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee0.00
Profits Per Employee-1.19M
Employee Count20
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Theriva Biologics is ―. Theriva Biologics’s PEG ratio is 0.00114.
PE Ratio―
PS Ratio0.00
PB Ratio0.17
Price to Fair Value0.17
Price to FCF-0.15
Price to Operating Cash Flow-0.13
PEG Ratio0.00114
Income Statement
In the last 12 months, Theriva Biologics had revenue of 0.00 and earned -25.25M in profits. Earnings per share was -2.08.
Revenue0.00
Gross Profit-108.00K
Operating Income-15.02M
Pretax Income-23.74M
Net Income-25.25M
EBITDA-14.91M
Earnings Per Share (EPS)-2.08
Cash Flow
In the last 12 months, operating cash flow was -16.67M and capital expenditures -35.00K, giving a free cash flow of -16.70M billion.
Operating Cash Flow-16.67M
Free Cash Flow-16.70M
Free Cash Flow per Share-0.36
Dividends & Yields
Theriva Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.32
52-Week Price Change-85.29%
50-Day Moving Average0.20
200-Day Moving Average0.33
Relative Strength Index (RSI)42.86
Average Volume (3m)8.88M
Important Dates
Theriva Biologics upcoming earnings date is May 19, 2026, After Close (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Theriva Biologics as a current ratio of 1.74, with Debt / Equity ratio of 17.09%
Current Ratio1.74
Quick Ratio1.74
Debt to Market Cap0.89
Net Debt to EBITDA0.70
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Theriva Biologics has paid 1.51M in taxes.
Income Tax1.51M
Effective Tax Rate-0.06
Enterprise Valuation
Theriva Biologics EV to EBITDA ratio is 0.53, with an EV/FCF ratio of 0.47.
EV to Sales0.00
EV to EBITDA0.53
EV to Free Cash Flow0.47
EV to Operating Cash Flow0.47
Balance Sheet
Theriva Biologics has $13.06M in cash and marketable securities with $2.63M in debt, giving a net cash position of $10.43M billion.
Cash & Marketable Securities$13.06M
Total Debt$2.63M
Net Cash$10.43M
Net Cash Per Share$0.23
Tangible Book Value Per Share-$0.35
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Theriva Biologics is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.00
Price Target Upside1900.00% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast83.25%